Japan’s ABsize Gets U.S. FDA Clearance For Phase I Pain-Patch Trials
This article was originally published in PharmAsia News
Executive Summary
Japanese biotech ABsize received clearance from U.S. FDA to conduct clinical trials of its AB001 anti-inflammatory transdermal patch for sprains and other acute pain.